Physician profile
Kevin J Adkins
NPI 1356311617
$1,521.07
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $541 · 2021: $45.36 · 2022: $21.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $537.00 | 2019-2021 | |
| Novo Nordisk INC | $254.42 | 2019-2020 | |
| Astellas Pharma US INC | $158.83 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $148.91 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $124.17 | 2019-2020 | |
| Glaxosmithkline, LLC. | $73.80 | 2019-2020 | |
| Amarin Pharma, INC. | $55.99 | 2020 | |
| Sunovion Pharmaceuticals INC. | $29.48 | 2020 | |
| Merck Sharp & Dohme LLC | $24.12 | 2019 | |
| Abbvie INC. | $21.74 | 2022 | |
| Mylan Specialty L.P. | $19.78 | 2019 | |
| Allergan, INC. | $18.01 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.71 | 2020 | |
| Genentech USA, INC. | $15.17 | 2019 | |
| Abbott Laboratories | $11.66 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.